Loading organizations...
§ Private Profile · Indian Harbour Beach, FL, USA
Healthcare diagnostics company developing AI-driven noninvasive tools for liver health assessment for healthcare providers.
Founded in 2015, Fibronostics is a healthcare diagnostics company based in Florida that develops artificial intelligence tools for assessing metabolic liver health and predicting various chronic disease risks. The organization processes blood samples through certified laboratories to deliver digital results to United States and Asian healthcare providers using proprietary diagnostic tests like LIVERFASt and HealthFACTR. Operating with a B2B commercial model, the medical technology company generated exactly 165,789 dollars in recent annual revenue alongside a negative EBITDA of 1,975,914 dollars. Fibronostics has raised between 6,500,000 and 8,000,000 dollars in total venture capital funding to scale its commercialization efforts and expand future research into kidney and lung diagnostics. The current executive leadership team includes Chief Executive Officer Sven Henrichwark, Chief Technology Officer John Lee, Chief Operating Officer Jonathan Berarducci, and Chief Scientific Officer Mona Munteanu.
Fibronostics has raised $8.0M across 1 funding round.
Fibronostics has raised $8.0M in total across 1 funding round.
Fibronostics has raised $8.0M in total across 1 funding round.
Fibronostics's investors include AT Capital Group, Elev8.vc.
Fibronostics has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 24, 2020 | $8M Series A | AT Capital Group, Elev8.VC | — | Announced |